Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
UCBCares: Providing Dedicated Patient Support
Clinical studies at UCB: How are medicines made and tested?
Twitter Feed
-
Discover what it's really like being a #scientist working on #MedicinesDevelopment. #InspiredByPatients #DrivenByScience https://t.co/AN8B3j8ITZ https://t.co/6R6d83Nm1t
— UCB News (@ucb_news) 12.12.2019 -
Can #AI help with early diagnosis of vertebral #fragilityfractures? What do you think @RSNA? #AITechnology #osteoporosis https://t.co/nuB5wAp01D
— UCB News (@ucb_news) 10.12.2019 -
#Parkinsons is forecast to affect 12.9 million people by 2040. Read how #wearables could accelerate the development of new therapeutic options for people living with PD https://t.co/h2SzmrVYik https://t.co/uo62nHIR9X
— UCB News (@ucb_news) 10.12.2019
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
